Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background and objectives: Diabetic kidney disease is an important complication of type 2 diabetes. In a phase 2b study, adding esaxerenone to renin-angiotensin system inhibitors dose dependently reduced the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and microalbuminuria. This 52-week phase 3 study further investigated the effects of esaxerenone on the urinary albumin-to-creatinine ratio in this patient group. Design, setting, participants, & measurements: In this multicenter, randomized, double-blind study, patients with type 2 diabetes and a urinary albumin-to-creatinine ratio of 45 to <300 mg/g creatinine treated with renin-angiotensin system inhibitors were randomized to esaxerenone or placebo for 52 weeks ( n =455). Esaxerenone was initiated at 1.25 mg/d and titrated to 2.5 mg/d on the basis of serum potassium monitoring. The primary endpoint was the proportion of patients achieving urinary albumin-to-creatinine ratio remission (<30 mg/g creatinine and ≥30% reduction from baseline on two consecutive occasions). Results: Overall, 49 (22%) and nine (4%) patients in the esaxerenone and placebo groups, respectively, achieved urinary albumin-to-creatinine ratio remission (absolute difference 18%; 95% confidence interval, 12% to 25%; P< 0.001). The percent change in urinary albumin-to-creatinine ratio from baseline to end of treatment was significantly higher with esaxerenone versus placebo (−58% versus 8%; geometric least-squares mean ratio to placebo 0.38, 95% confidence interval, 0.33 to 0.44). There was a significant improvement with esaxerenone versus placebo in time to first remission (hazard ratio, 5.13; 95% confidence interval, 3.27 to 8.04) and time to first transition to urinary albumin-to-creatinine ratio ≥300 mg/g creatinine (hazard ratio, 0.23; 95% confidence interval, 0.11 to 0.48). More patients had a serum potassium level ≥6.0 or ≥5.5 mEq/L on two consecutive measurements in the esaxerenone group (20 [9%]) versus placebo (5 [2%]); these events were asymptomatic and resolved after dosage reduction or treatment discontinuation. Conclusions: Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Novel nonsteroidal MRA, such as fi nerenone and esaxerenone, are more selective for mineralocorticoid receptors and have been noted to offer similar reductions in albuminuria but with a lower risk of hyperkalemia.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esaxerenone lowered BP and albuminuria with limited changes in potassium, but long-term studies with clinical end points are lacking (85).”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Esaxerenone, another ns-MRA, has also been shown to lower urinary albumin excretion.”
The cited source says what the claim attributes to it.
In the citing paper
“However, the long-term kidney and cardiovascular bene fi ts of esaxerenone have not been established, and regulatory approval for esaxerenone is not widespread.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to fi nerenone, another nonsteroidal MRA, esaxerenone, has also been shown to lower albumin excretion.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [161]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation
Cited by
Items 201–246 of 246
Teh, J. W., Comerford, G., Surlis, G., Curneen, J. M. G., Krewer, F., Smyth, A., Lappin, D. W. P., McEvoy, J. W., Dennedy, M. C., & Judge, C. S. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004323 · Cited by 1
Comparison of Insomnia Risk between Spironolactone and Esaxerenone in Individuals with Hypertension
Nakayama, T., Kaneko, H., Suzuki, Y., Okada, A., Morita, H., Fujiu, K., Takeda, N., Azegami, T., Yokoo, T., Takeda, N., et al. (2026) · JMA Journal · doi:10.31662/jmaj.2025-0554 · Cited by 1
“Furthermore, numerous studies have indicated their efficacy in heart failure and chronic kidney disease associated with diabetes (5), (6), (7), (8), (30) .”
Chen, R., Zhang, M., & Zhang, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2430806 · Cited by 1
RetractedYamaguchi, H., Hosojima, M., Kabasawa, H., Ito, Y., Suzuki, Y., Saito, A., Arakawa, M., & Narita, I. (2022) · CEN Case Reports · doi:10.1007/s13730-022-00766-3 · Cited by 1
“For treatment of diabetic kidney disease, two recent randomized controlled trials—ESAX-DN [14] and FIDELIO-DKD [15]—have provided evidence for adding non-steroidal selective MR blockers to existing renin–angiotensin–aldosterone inhibitors.”
BackgroundMethodDaimon, S. (2024) · Clinical Nephrology - Case Studies · doi:10.5414/cncs111078 · Cited by 1
Kario, K., Shiosakai, K., & Taguchi, T. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14857 · Cited by 3
“It has exhibited antihypertensive and organ-protective effects in patients with various types of hypertension, 11,12 including nocturnal hypertension.”
BackgroundMineralocorticoid receptor blockers for moderate kidney dysfunction: more merit than ever?
Mukoyama, M., Kuwabara, T., & Adachi, M. (2021) · Hypertension Research · doi:10.1038/s41440-021-00690-6 · Cited by 1
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
“The ESAX-DN trial demonstrated that esaxerenone reduced the progression of albuminuria and resulted in an albuminuria remission rate of 22% in the participants [79].”
BackgroundResearch Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease
王, 璇. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131065
Нестероїдні антагоністи мінералокортикоїдних рецепторів та кардіоренальний контінуум
Botsiurko, Y. V. (2023) · Прикарпатський вісник наукового товариства імені Шевченка ПУЛЬС · doi:10.21802/2304-7437-2023-19(67)-70-75
Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System: Drei neue Wirkstoffklassen
van der Giet, M. (2024) · CardioVasc · doi:10.1007/s15027-023-3500-0
Tamura, K. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.777
Clinical benefits and uncertainties of treatment with esaxerenone in primary aldosteronism
Yoshida, Y., & Shibata, H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01869-3
“In contrast, esaxerenone reportedly has good antihypertensive and anti-proteinuric/albuminuric effects in diabetic patients with proteinuria and albuminuria (ESAX-DN) [7] unless their estimated glemerular fi ltration rate is 30 mL/min/ 1.73 m 2 .”
InfluentialAktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01235-4
Pliças, M. M. D., da Silva, B. M., & Almeida, E. (2024) · Nefrología · doi:10.1016/j.nefro.2024.10.004
Diabetic Nephropathy in Advanced Age Patients
Argyropoulos, C., & Roumelioti, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-68460-9_8
Aktueller Stand der Nephroprotektion in der Diabetologie
Schmieder, R. E., & Striepe, K. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00258-6
“Für Patienten mit einem T2D, einer Albuminurie und normalen Blutdruckwerten ist eine RAS-Blocker-Therapie zu erwägen.”
田, 洋. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551501
Kuwabara, S., Kameda, H., Yokozeki, K., Miya, A., Nomoto, H., Cho, K. Y., Nakamura, A., Koyanagawa, N., Yamamoto, K., Takeuchi, J., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0639
“Treatment with Esax also reduced the UACR of the subjects with diabetes and albuminuria, which suggests that it may have a renoprotective effect, as shown in pre‐ vious clinical studies [26, 27].”
ファーマコメトリクスを用いた医薬品の推奨臨床用量の正当化 : 非ステロイド型ミネラルコルチコイド受容体拮抗薬エサキセレノン及び抗HER2抗体薬物複合体トラスツズマブ デルクステカン
Yoshihara, K. (2024) · Institutional Repositories DataBase (IRDB)
Gentile, M., D’Angelo, M., Varì, M. R., Bolla, A. M., Bianco, M., & Scarpioni, R. (2025) · Diabetology · doi:10.3390/diabetology6120144
“Esaxerenone, instead, has been clinically available in Japan since 2019 for treating hypertension and has been proved to have a higher incidence of urinary albumin remission in patients with type 2 diabetes with high levels of albuminuria treated with a RAS inhibitor [92].”
Protocolo de diagnóstico e tratamento da hipertensão arterial sistêmica no Diabetes Mellitus
Oliveira, C. A. D. [. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Rodrigues‐Braz, D. (2023) · theses.fr (ABES) · doi:10.70675/b5ea077fz3ec6z4238z8e5ez326aeef1629e
Katsuya, T., Kario, K., Ohishi, M., Shimosawa, T., Shiosakai, K., Furugori, T., Taguchi, T., & the EXCITE‐HT investigators (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70314
Mineralocorticoid Receptor Antagonists for Renoprotection and Cardioprotection in CKD
Iatridi, F., & Theodorakopoulou, M. P. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_16
Rapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead
Wang, S. S. Y., Chan, Y. Z., Luo, X. R., Tan, N. A. M. R., Klein, M., & Javaid, M. M. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-240
Benefits of renin angiotensin aldosterone system blockage
Turgut, F. H., & Abdel‐Rahman, E. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34069-7.00030-6
Ohara, M., Omachi, T., Takehana, N., Fujikawa, T., Osaka, N., Irie, S., Terasaki, M., Mori, Y., Matsui, T., & Yamagishi, S. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70412
“In addition, previous clinical studies have shown that esaxerenone reduces albuminuria in patients with type 2 diabetes mellitus and albuminuria receiving RAS inhibitor therapy, further supporting the albuminuria-lowering effects of MR blockade in this population 15, 22 .”
Regulation of the Mineralocorticoid Receptor in Physiology and Disease
Young, M. J., Fuller, P. J., Meijer, O. C., Cole, T. J., Kanki, M., Yang, J., Ho, Q. V., Karthigan, N., & Heanue, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100156
韩, 昱. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.54263
Sex in CKD trials: representation and treatment effects of cardio-renoprotective therapies
Bellos, I., Αθανασίου, Μ., Nikita, K. S., & Benetou, V. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag199
Phenotype‐Guided Sodium–Volume Strategy for Perfect 24‐Hour Blood Pressure Control
Kario, K. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.052031
Macrophage–Fibroblast Crosstalk in Kidney Injury: A Narrative Review
Qiang, P., Han, L., Lv, R., Dong, Z., Ma, T., Wang, X., & Xu, Q. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188173
“In ESAX-DN, esaxerenone reduced the urinary albumin-to-creatinine ratio (UACR) and increased the rate of albuminuria remission in patients receiving a renin–angiotensin system inhibitor [124].”
Araripe, D. A., Iljin, M., Bange, H., Price, L., Liu, R., van der Es, D., Heitman, L. H., Peters, D. J. M., & van Westen, G. J. P. (2026) · SLAS DISCOVERY · doi:10.1016/j.slasd.2026.100338
Dose-Specific Network Meta-Analysis of Mineralocorticoid Receptor Antagonists in CKD
Korucu, B., Colak, A., Mustafa, R., Earley, A., & Wheeler, D. C. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107084
Komori, T., Lauder, L., & Kario, K. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag273
Sánchez‐Bayuela, T., Barrera‐Chimal, J., & Jaisser, F. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01125-6 · Cited by 1
Acta Bioclínica Volúmen 13, N° 26: Julio - Diciembre 2023
- (2023) · Acta Bioclínica
Ohishi, M., Kario, K., Ohbayashi, H., Ishii, H., Kato, M., Nozaki, M., Abiru, N., Fukui, T., Nomura, K., Fukushima, Y., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02779-2
Zaidi, N. E., Azizan, E. A. B. A., & Ali, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102321
“…(ESAX-HTN trial) [212], blood pressure reduction and urinary albumin suppression in diabetic kidney disease (ESAX-DN and EX-DKD trials) [213,214], left ventricular mass index regression in hypertensive patients with left ventricular hypertrophy (ESES-LVH trial) [215], blood pressure…”
Tian, Z., & Li, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1983608
“All eight included studies (Bakris et al., 2020; Bakris et al., 2015; Ito et al., 2020; Ito et al., 2019; Katayama et al., 2017; Pitt et al., 2021; Tanaka et al., 2025; Wada et al., 2021) were assessed as having low risk of bias across all five domains of the Cochrane RoB 2 tool for each…”
InfluentialSagawa, T., Umehara, K., Izumi, M., Kawamura, K., & Fujikawa, K. (2026) · Medical Oncology · doi:10.1007/s12032-026-03498-x
Chen, Q., Wei, G., Wang, Y., Li, X., Zhao, Q., Zhu, L., Xiao, Q., & Xiong, X. (2024) · doi:10.3389/fphar.2024.1338044.s001
Jiang, X., Zhang, Z., Li, C., Zhang, S., Su, Q., Yang, S., Liu, X., Hu, Y., & Pu, X. (2022) · doi:10.3389/fphar.2022.896947.s003
Wu, Y., Lin, H., Tao, Y., Xu, Y., Chen, J., Jia, Y., & Zheng, Z. (2022) · doi:10.3389/fphar.2022.967317.s001
Metadata
- Authors
- Ito, S., Kashihara, N., Shikata, K., Nangaku, M., Wada, T., Okuda, Y., & Sawanobori, T.
- Affiliations
- Tohoku University (JP)
- Kawasaki Medical School (JP)
- Okayama University Hospital (JP)
- The University of Tokyo (JP)
- Kanazawa University (JP)
- Daiichi-Sankyo (Japan) (JP)
- Corresponding author
- Ito, Sadayoshi
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2020-11-25
- Volume
- 15
- Issue
- 12
- Pages
- 1715-1727
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC7769030
- OpenAlex
- W3107151441
- Cited by
- 234
- References
- 42
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 46 · 2023: 46 · 2022: 46 · 2021: 25 · 2020: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Co., Ltd
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- One, type 2 diabetes, microalbuminuria, diabetic nephropathy, albumin-creatinine ratio, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, serum potassium, renal protection, hospitalization
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Creatinine, Diabetes Mellitus, Type 2, Female, Humans, Japan, Kidney, Male, Middle Aged, Pyrroles, Remission Induction, Risk Factors, Sulfones, Time Factors, Biomarkers, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.